secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001390478-24-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Life Sciences Q2 2024 net loss $7.5M; cash $9.1M; $21M capital raise; IDMC supports REGAL
--------------------------------------------------------------------------------

- Net loss $7.5M ($0.13/share) vs $8.8M ($0.31/share) in Q2 2023; R&D expenses $5.2M.
- Cash $9.1M at June 30; subsequent $21M gross proceeds from premium-priced registered direct offering.
- IDMC recommends continue Phase 3 REGAL (GPS) in AML without modifications; interim analysis expected by Q4 2024.
- Phase 2a SLS009 in r/r AML: ORR 33% (60mg QW), 50% (30mg BIW), 100% in ASXL1 mutant cohort.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047824000016/0001390478-24-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047824000016/sls-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001390478-24-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer